Gastric adenoma

Summary

Gastric adenoma (MONDO:0006221) is a cancer and 11 clinical trials. Top therapeutic interventions include bupivacaine, menthol, and carnosine. A subtype of digestive system adenoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 11

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	gastric adenoma
Mondo ID	MONDO:0006221
EFO	EFO:1000268
NCIT	C7699
UMLS	C0149826
MedGen	56204
Anatomy (UBERON)	UBERON:0000945
Is cancer (heuristic)	yes

Also known as: adenoma of stomach · adenoma of the stomach · gastric adenoma · stomach adenoma

Disease family

This is a subtype of digestive system adenoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › adenoma › digestive system adenoma › gastric adenoma

Related subtypes (5): colorectal adenoma, bile duct adenoma, gallbladder adenoma, Warthin tumor, adenoma of small intestine

Subtypes (1): pyloric gland adenoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 11.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	9
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01157598	PHASE3	UNKNOWN	Efficacy of Bispectral Index Monitoring for Midazolam and Meperidine Induced Sedation During Endoscopic Submucosal Dissection
NCT01411189	PHASE3	COMPLETED	Phase III Open-labeled Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy
NCT04665687	Not specified	RECRUITING	Clinical Application of Genetic Sequencing of Early Gastric Cancer and Gastric Adenoma Patients
NCT07161479	Not specified	RECRUITING	Argon Plasma Coagulation Versus Endoscopic Mucosal Resection for Gastric Adenoma (CLER-GA)
NCT01806753	Not specified	COMPLETED	Performance of Endoscopic Submucosal Dissection According to the Sedation Method
NCT01824953	Not specified	COMPLETED	Long-term Follow-up Prognosis of Atrophic Gastritis After 3 Years
NCT01961752	Not specified	COMPLETED	The Efficacy of Topical Bupivacaine and Triamcinolone Acetonide Injection in the Relief of Pain After Endoscopic Submucosal Dissection for Gastric Neoplasia: A Randomized Double-blind, Placebo-controlled Trial
NCT02243618	Not specified	COMPLETED	The Effect of Proton Pump Inhibitor and Polaprezinc Combination Therapy for Healing of Endoscopic Submucosal Dissection-induced Ulcer
NCT02504164	Not specified	COMPLETED	Effect of Midazolam Premedication on the Satisfaction Levels of Patients After Endoscopic Submucosal Dissection
NCT03546257	Not specified	UNKNOWN	Magnifying Endoscopy With Narrow Band Imaging Versus Endoscopic Ultrasonography for Prediction of Tumor Invasion Depth in Early Gastric Cancer: A Prospective Comparative Study
NCT04602689	Not specified	COMPLETED	Fibrin Glue After ESD for High Risk Patients of Bleeding

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BUPIVACAINE	4	1
MENTHOL	4	1
CARNOSINE	3	2
LEVOMENTHOL	3	1
REBAMIPIDE	3	1
CHEMBL1703336	0	1